Annexon reports phase 1 results for anx1502, its oral small molecule inhibitor of the classical complement pathway

Target levels of active drug achieved in healthy volunteers with oral twice-daily dosing; supportive impact on pharmacodynamic biomarker of complement activity

ANNX Ratings Summary

ANNX Quant Ranking